Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Fosigotifator
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Calico Announces Fosigotifator Selected for FDA Pilot Program for White Matter Disease
Details : ABBV-CLS-7262 (fosigotifator) is an eIF2B activator, a factor that is essential for protein synthesis and a key regulator of the ISR. It is being investigated for vanishing white matter disease.
Product Name : ABBV-CLS-7262
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 06, 2024
Lead Product(s) : Fosigotifator
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fosigotifator
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ABBV-CLS-7262 is an eIF2B activator which targets eIF2B, a guanine nucleotide exchange factor that is essential for protein synthesis and a key regulator of the ISR. It is being investigated for vanishing white matter disease.
Product Name : ABBV-CLS-7262
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 26, 2023
Lead Product(s) : Fosigotifator
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ABBV 579 is an IO asset, it is being studied in participants with locally advanced or metastatic tumors. As part of the collaboration, Calico pursues discovery-stage research and development utilizing state-of-the-art technology and advanced computing ca...
Product Name : ABBV 579
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 27, 2021
Reset All
